Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for CRE Eradication
NCT04790565Phase 3Completed
- Sponsor
- Rambam Health Care Campus
- Start
- Apr 2021
- Primary completion
- Jun 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, open-label trial of allogeneic fecal microbiota in Enterobacteriaceae colonization, sponsored by Rambam Health Care Campus. Primary endpoint: Carbapenem-resistant Enterobacteriaceae eradication at 28 days. Started Apr 2021; status: completed.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Enterobacteriaceae colonization
Beyond the preview
Go deeper on NCT04790565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04790565.